Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	histone H3K4 monomethyltransferase activity	SETD1A KMT2C KMT2D KMT2A	7.54e-09	8	66	4	GO:0140945
GeneOntologyMolecularFunction	histone H3K4 trimethyltransferase activity	SETD1A KMT2C KMT2D KMT2A	2.25e-08	10	66	4	GO:0140999
GeneOntologyMolecularFunction	histone H3K4 methyltransferase activity	SETD1A KMT2C KMT2D KMT2A	5.07e-07	20	66	4	GO:0042800
GeneOntologyMolecularFunction	histone H3 methyltransferase activity	SETD1A KMT2C KMT2D KMT2A	1.34e-05	44	66	4	GO:0140938
GeneOntologyMolecularFunction	protein-lysine N-methyltransferase activity	SETD1A KMT2C KMT2D KMT2A	7.56e-05	68	66	4	GO:0016279
GeneOntologyMolecularFunction	lysine N-methyltransferase activity	SETD1A KMT2C KMT2D KMT2A	8.01e-05	69	66	4	GO:0016278
GeneOntologyMolecularFunction	histone methyltransferase activity	SETD1A KMT2C KMT2D KMT2A	8.95e-05	71	66	4	GO:0042054
GeneOntologyMolecularFunction	protein methyltransferase activity	SETD1A KMT2C KMT2D KMT2A	3.76e-04	103	66	4	GO:0008276
GeneOntologyMolecularFunction	N-methyltransferase activity	SETD1A KMT2C KMT2D KMT2A	4.05e-04	105	66	4	GO:0008170
GeneOntologyMolecularFunction	microtubule binding	MAP1A BCL2L11 DNM3 MAST1 DIAPH3 ENKD1	5.36e-04	308	66	6	GO:0008017
GeneOntologyMolecularFunction	transforming growth factor beta receptor activity	AMHR2 TGFBR3L	8.20e-04	13	66	2	GO:0005024
GeneOntologyMolecularFunction	cytoskeletal protein binding	SPTBN4 MAP1A BCL2L11 TPRN DNM3 MAST1 DIAPH3 WASF1 TNS1 SHANK3 ENKD1	8.83e-04	1099	66	11	GO:0008092
GeneOntologyMolecularFunction	histone modifying activity	SETD1A KMT2C KMT2D KMT2A KDM6B	9.61e-04	229	66	5	GO:0140993
GeneOntologyMolecularFunction	actin binding	SPTBN4 MAP1A TPRN DIAPH3 WASF1 TNS1 SHANK3	1.00e-03	479	66	7	GO:0003779
GeneOntologyMolecularFunction	histone methyltransferase binding	WIZ ZNF335	1.59e-03	18	66	2	GO:1990226
GeneOntologyMolecularFunction	transmembrane receptor protein serine/threonine kinase activity	AMHR2 TGFBR3L	1.97e-03	20	66	2	GO:0004675
GeneOntologyMolecularFunction	glutamate receptor binding	MAP1A DNM3 SHANK3	2.45e-03	81	66	3	GO:0035254
GeneOntologyMolecularFunction	S-adenosylmethionine-dependent methyltransferase activity	SETD1A KMT2C KMT2D KMT2A	2.53e-03	172	66	4	GO:0008757
GeneOntologyMolecularFunction	cytoskeletal anchor activity	SPTBN4 MAP1A	2.83e-03	24	66	2	GO:0008093
GeneOntologyMolecularFunction	tubulin binding	MAP1A BCL2L11 DNM3 MAST1 DIAPH3 ENKD1	2.88e-03	428	66	6	GO:0015631
GeneOntologyMolecularFunction	chromatin binding	SOX10 TICRR HNF1A POLR2A KMT2A ARID3C RERE KDM6B	2.93e-03	739	66	8	GO:0003682
GeneOntologyCellularComponent	histone methyltransferase complex	SETD1A KMT2C KMT2D ZNF335 KMT2A KDM6B	1.33e-07	75	66	6	GO:0035097
GeneOntologyCellularComponent	methyltransferase complex	SETD1A KMT2C KMT2D ZNF335 KMT2A KDM6B	1.17e-06	108	66	6	GO:0034708
GeneOntologyCellularComponent	MLL3/4 complex	KMT2C KMT2D KDM6B	6.48e-06	12	66	3	GO:0044666
GeneOntologyCellularComponent	ESCRT I complex	UBAP1L DIAPH3	6.35e-04	12	66	2	GO:0000813
MousePheno	abnormal pre-Botzinger complex morphology	DBX1 KDM6B	1.75e-05	2	59	2	MP:0010745
Domain	Post-SET_dom	SETD1A KMT2C KMT2D KMT2A	2.51e-07	16	66	4	IPR003616
Domain	PostSET	SETD1A KMT2C KMT2D KMT2A	2.51e-07	16	66	4	SM00508
Domain	POST_SET	SETD1A KMT2C KMT2D KMT2A	2.51e-07	16	66	4	PS50868
Domain	FYrich_C	KMT2C KMT2D KMT2A	4.19e-07	5	66	3	IPR003889
Domain	FYrich_N	KMT2C KMT2D KMT2A	4.19e-07	5	66	3	IPR003888
Domain	FYRC	KMT2C KMT2D KMT2A	4.19e-07	5	66	3	SM00542
Domain	FYRN	KMT2C KMT2D KMT2A	4.19e-07	5	66	3	SM00541
Domain	FYRN	KMT2C KMT2D KMT2A	4.19e-07	5	66	3	PF05964
Domain	FYRC	KMT2C KMT2D KMT2A	4.19e-07	5	66	3	PF05965
Domain	FYRC	KMT2C KMT2D KMT2A	4.19e-07	5	66	3	PS51543
Domain	FYRN	KMT2C KMT2D KMT2A	4.19e-07	5	66	3	PS51542
Domain	SET	SETD1A KMT2C KMT2D KMT2A	1.31e-05	41	66	4	PF00856
Domain	SET	SETD1A KMT2C KMT2D KMT2A	2.08e-05	46	66	4	SM00317
Domain	SET_dom	SETD1A KMT2C KMT2D KMT2A	2.90e-05	50	66	4	IPR001214
Domain	SET	SETD1A KMT2C KMT2D KMT2A	2.90e-05	50	66	4	PS50280
Domain	EPHD	KMT2C KMT2D KMT2A	6.19e-05	22	66	3	PS51805
Domain	PAM2	ATXN2L HELZ	4.36e-04	9	66	2	PF07145
Domain	Ataxin-2_C	ATXN2L HELZ	4.36e-04	9	66	2	IPR009818
Domain	HMG_box	SOX10 KMT2C KMT2D	8.70e-04	53	66	3	PF00505
Domain	HMG	SOX10 KMT2C KMT2D	9.19e-04	54	66	3	SM00398
Domain	AT_hook	KMT2C KMT2A	1.43e-03	16	66	2	PF02178
Domain	TSP_1	ADAMTS7 ADAMTS14 SSPOP	1.44e-03	63	66	3	PF00090
Domain	HMG_box_dom	SOX10 KMT2C KMT2D	1.57e-03	65	66	3	IPR009071
Domain	TSP1	ADAMTS7 ADAMTS14 SSPOP	1.57e-03	65	66	3	SM00209
Domain	TSP1_rpt	ADAMTS7 ADAMTS14 SSPOP	1.57e-03	65	66	3	IPR000884
Domain	TSP1	ADAMTS7 ADAMTS14 SSPOP	1.57e-03	65	66	3	PS50092
Domain	ZP_dom	ZP1 TGFBR3L	1.62e-03	17	66	2	IPR001507
Domain	Zona_pellucida	ZP1 TGFBR3L	1.62e-03	17	66	2	PF00100
Domain	VWC_out	VWCE SSPOP	2.02e-03	19	66	2	SM00215
Domain	PLAC	ADAMTS7 ADAMTS14	2.02e-03	19	66	2	PS50900
Domain	PLAC	ADAMTS7 ADAMTS14	2.02e-03	19	66	2	IPR010909
Domain	PHD	KMT2C KMT2D KMT2A	2.37e-03	75	66	3	PF00628
Domain	Znf_PHD-finger	KMT2C KMT2D KMT2A	2.75e-03	79	66	3	IPR019787
Domain	ADAM_spacer1	ADAMTS7 ADAMTS14	2.97e-03	23	66	2	IPR010294
Domain	ADAM_spacer1	ADAMTS7 ADAMTS14	2.97e-03	23	66	2	PF05986
Domain	tRNA-bd_arm	RPRD2 CNOT3	3.23e-03	24	66	2	IPR010978
Domain	Peptidase_M12B_ADAM-TS	ADAMTS7 ADAMTS14	3.23e-03	24	66	2	IPR013273
Domain	PHD	KMT2C KMT2D KMT2A	3.85e-03	89	66	3	SM00249
Domain	-	HNF1A POU6F2	4.08e-03	27	66	2	1.10.260.40
Domain	AT_hook	KMT2C KMT2A	4.08e-03	27	66	2	SM00384
Domain	AT_hook_DNA-bd_motif	KMT2C KMT2A	4.08e-03	27	66	2	IPR017956
Domain	Znf_PHD	KMT2C KMT2D KMT2A	4.10e-03	91	66	3	IPR001965
Domain	ZF_PHD_2	KMT2C KMT2D KMT2A	4.63e-03	95	66	3	PS50016
Domain	Lambda_DNA-bd_dom	HNF1A POU6F2	4.70e-03	29	66	2	IPR010982
Domain	ZF_PHD_1	KMT2C KMT2D KMT2A	4.76e-03	96	66	3	PS01359
Pathway	REACTOME_FORMATION_OF_WDR5_CONTAINING_HISTONE_MODIFYING_COMPLEXES	SETD1A KMT2C KMT2D KMT2A	9.28e-06	42	45	4	M48018
Pathway	WP_HISTONE_MODIFICATIONS	SETD1A KMT2C KMT2D KMT2A	5.32e-05	65	45	4	M39374
Pathway	REACTOME_PKMTS_METHYLATE_HISTONE_LYSINES	SETD1A KMT2C KMT2D KMT2A	7.12e-05	70	45	4	M27231
Pathway	REACTOME_FORMATION_OF_WDR5_CONTAINING_HISTONE_MODIFYING_COMPLEXES	SETD1A KMT2D KMT2A	2.37e-04	38	45	3	MM17073
Pathway	REACTOME_RUNX1_REGULATES_GENES_INVOLVED_IN_MEGAKARYOCYTE_DIFFERENTIATION_AND_PLATELET_FUNCTION	SETD1A KMT2C KMT2D KMT2A	2.43e-04	96	45	4	M27792
Pathway	REACTOME_O_GLYCOSYLATION_OF_TSR_DOMAIN_CONTAINING_PROTEINS	ADAMTS7 ADAMTS14 SSPOP	2.56e-04	39	45	3	M27417
Pathway	REACTOME_O_GLYCOSYLATION_OF_TSR_DOMAIN_CONTAINING_PROTEINS	ADAMTS7 ADAMTS14 SSPOP	2.56e-04	39	45	3	MM15165
Pathway	REACTOME_RUNX1_REGULATES_GENES_INVOLVED_IN_MEGAKARYOCYTE_DIFFERENTIATION_AND_PLATELET_FUNCTION	SETD1A KMT2D KMT2A	3.67e-04	44	45	3	MM15527
Pathway	REACTOME_PKMTS_METHYLATE_HISTONE_LYSINES	SETD1A KMT2D KMT2A	4.19e-04	46	45	3	MM14933
Pathway	REACTOME_ACTIVATION_OF_ANTERIOR_HOX_GENES_IN_HINDBRAIN_DEVELOPMENT_DURING_EARLY_EMBRYOGENESIS	KMT2C KMT2D ZNF335 POLR2A	6.05e-04	122	45	4	M29689
Pubmed	Skirting the pitfalls: a clear-cut nomenclature for H3K4 methyltransferases.	SETD1A KMT2C KMT2D KMT2A	8.23e-10	8	66	4	23130995
Pubmed	The plasticity of WDR5 peptide-binding cleft enables the binding of the SET1 family of histone methyltransferases.	SETD1A KMT2C KMT2D KMT2A	8.23e-10	8	66	4	22266653
Pubmed	Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.	SETD1A KMT2C KMT2D KMT2A	1.48e-09	9	66	4	22665483
Pubmed	Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.	SETD1A KMT2C KMT2D KMT2A	5.79e-09	12	66	4	27563068
Pubmed	Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription.	KMT2C KMT2D KMT2A	6.53e-09	3	66	3	23932714
Pubmed	Impact of WIN site inhibitor on the WDR5 interactome.	SETD1A KMT2C KMT2D KMT2A RERE	1.92e-08	43	66	5	33472061
Pubmed	A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity.	KMT2C KMT2D KMT2A	2.61e-08	4	66	3	23129768
Pubmed	The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers.	KMT2C KMT2D KMT2A	2.61e-08	4	66	3	24081332
Pubmed	Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition.	KMT2C KMT2D KMT2A KDM6B	6.91e-08	21	66	4	27626377
Pubmed	New nomenclature for chromatin-modifying enzymes.	SETD1A KMT2C KMT2D KMT2A KDM6B	8.18e-08	57	66	5	18022353
Pubmed	Structural basis for activity regulation of MLL family methyltransferases.	SETD1A KMT2C KMT2D KMT2A	8.43e-08	22	66	4	26886794
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	ATXN2L SETD1A KMT2C KMT2D WIZ POLR2A KMT2A PTPN23 RPRD2 DIAPH3	8.46e-08	549	66	10	38280479
Pubmed	GRWD1-WDR5-MLL2 Epigenetic Complex Mediates H3K4me3 Mark and Is Essential for Kaposi's Sarcoma-Associated Herpesvirus-Induced Cellular Transformation.	SETD1A KMT2D KMT2A	1.30e-07	6	66	3	34933446
Pubmed	MLL associates specifically with a subset of transcriptionally active target genes.	KMT2D POLR2A KMT2A	1.30e-07	6	66	3	16199523
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	SETD1A KMT2C KMT2D WIZ BCL2L11 ADAMTS7 BICRA ZNF335 POLR2A A4GALT KDM6B ZNF687 RAD9A	1.34e-07	1105	66	13	35748872
Pubmed	Clustered PHD domains in KMT2/MLL proteins are attracted by H3K4me3 and H3 acetylation-rich active promoters and enhancers.	KMT2C KMT2D KMT2A	2.27e-07	7	66	3	36598580
Pubmed	Interaction network of human early embryonic transcription factors.	SETD1A KMT2C KMT2D WIZ BICRA BCORL1 KMT2A RERE	3.43e-07	351	66	8	38297188
Pubmed	Identification and characterization of a novel human PP1 phosphatase complex.	SETD1A KMT2C KMT2D POLR2A	3.58e-07	31	66	4	20516061
Pubmed	Human transcription factor protein interaction networks.	SOX10 SETD1A KMT2C HNF1A KMT2D WIZ BICRA BCORL1 KMT2A HELZ RPRD2 RERE CNOT3 ZNF687	3.83e-07	1429	66	14	35140242
Pubmed	Physical Interactions and Functional Coordination between the Core Subunits of Set1/Mll Complexes and the Reprogramming Factors.	SETD1A KMT2D KMT2A	5.44e-07	9	66	3	26691508
Pubmed	Human CpG binding protein interacts with MLL1, MLL2 and hSet1 and regulates Hox gene expression.	SETD1A KMT2D KMT2A	1.07e-06	11	66	3	18082152
Pubmed	Dynamic patterns of histone H3 lysine 4 methyltransferases and demethylases during mouse preimplantation development.	SETD1A KMT2C KMT2A	1.84e-06	13	66	3	24619213
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	ATXN2L KMT2D ZNF335 POLR2A KMT2A HELZ RERE CNOT3 USP19 ZNF687	1.93e-06	774	66	10	15302935
Pubmed	Identification of Jmjd3 as an Essential Epigenetic Regulator of Hox Gene Temporal Collinear Activation for Body Axial Patterning in Mice.	SETD1A KMT2C KMT2A KDM6B	2.35e-06	49	66	4	34368113
Pubmed	Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival.	SETD1A KMT2C KMT2D KMT2A	2.55e-06	50	66	4	37974198
Pubmed	Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus.	KMT2D POLR2A KMT2A	2.92e-06	15	66	3	14992727
Pubmed	Mll3 and Mll4 Facilitate Enhancer RNA Synthesis and Transcription from Promoters Independently of H3K4 Monomethylation.	KMT2C KMT2D	3.55e-06	2	66	2	28483418
Pubmed	The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape.	KMT2C KMT2D	3.55e-06	2	66	2	34156443
Pubmed	Jumonji Domain-containing Protein-3 (JMJD3/Kdm6b) Is Critical for Normal Ovarian Function and Female Fertility.	AMHR2 KDM6B	3.55e-06	2	66	2	35396990
Pubmed	KMT2C/D COMPASS complex-associated diseases [KCDCOM-ADs]: an emerging class of congenital regulopathies.	KMT2C KMT2D	3.55e-06	2	66	2	31924266
Pubmed	Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma.	KMT2C KMT2D	3.55e-06	2	66	2	27280393
Pubmed	Loss of MLL3/4 decouples enhancer H3K4 monomethylation, H3K27 acetylation, and gene activation during embryonic stem cell differentiation.	KMT2C KMT2D	3.55e-06	2	66	2	36869380
Pubmed	Set1 and MLL1/2 Target Distinct Sets of Functionally Different Genomic Loci In Vivo.	KMT2D KMT2A	3.55e-06	2	66	2	26711341
Pubmed	Histone H3K4 monomethylation catalyzed by Trr and mammalian COMPASS-like proteins at enhancers is dispensable for development and viability.	KMT2C KMT2D	3.55e-06	2	66	2	28967912
Pubmed	Mll2 is required for H3K4 trimethylation on bivalent promoters in embryonic stem cells, whereas Mll1 is redundant.	KMT2D KMT2A	3.55e-06	2	66	2	24423662
Pubmed	Crucial roles of mixed-lineage leukemia 3 and 4 as epigenetic switches of the hepatic circadian clock controlling bile acid homeostasis in mice.	KMT2C KMT2D	3.55e-06	2	66	2	25346535
Pubmed	Granulocyte/macrophage colony-stimulating factor causes a paradoxical increase in the BH3-only pro-apoptotic protein Bim in human neutrophils.	CSF2RB BCL2L11	3.55e-06	2	66	2	20705940
Pubmed	Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.	KMT2C KMT2D	3.55e-06	2	66	2	36601880
Pubmed	SET1 and p300 act synergistically, through coupled histone modifications, in transcriptional activation by p53.	SETD1A KMT2C KMT2A	3.59e-06	16	66	3	23870121
Pubmed	H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation.	SETD1A KMT2C KMT2D	3.59e-06	16	66	3	24368734
Pubmed	Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism.	ATXN2L SETD1A KMT2D WIZ POLR2A KMT2A ZNF687	3.88e-06	341	66	7	32971831
Pubmed	PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex.	SETD1A KMT2C KMT2D	5.22e-06	18	66	3	17500065
Pubmed	Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.	SETD1A KMT2C KMT2D	7.27e-06	20	66	3	29785026
Pubmed	Genetic interaction mapping in mammalian cells using CRISPR interference.	SETD1A KMT2D KMT2A CNOT3	9.32e-06	69	66	4	28481362
Pubmed	Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment.	KMT2D KMT2A	1.06e-05	3	66	2	26902498
Pubmed	Histone demethylase Jmjd3 regulates osteoblast apoptosis through targeting anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bim.	BCL2L11 KDM6B	1.06e-05	3	66	2	26795455
Pubmed	MLL histone methylases regulate expression of HDLR-SR-B1 in presence of estrogen and control plasma cholesterol in vivo.	KMT2D KMT2A	1.06e-05	3	66	2	23192982
Pubmed	Mutations of PTCH1, MLL2, and MLL3 are not frequent events in hepatoblastoma.	KMT2C KMT2D	1.06e-05	3	66	2	22183980
Pubmed	Set1/MLL complex is indispensable for the transcriptional ability of heat shock transcription factor 2.	SETD1A KMT2A	1.06e-05	3	66	2	26478434
Pubmed	The coactivator host cell factor-1 mediates Set1 and MLL1 H3K4 trimethylation at herpesvirus immediate early promoters for initiation of infection.	SETD1A KMT2A	1.06e-05	3	66	2	17578910
Pubmed	Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.	KMT2D KMT2A	1.06e-05	3	66	2	30315824
Pubmed	HOXC6 Is transcriptionally regulated via coordination of MLL histone methylase and estrogen receptor in an estrogen environment.	KMT2C KMT2D	1.06e-05	3	66	2	21683083
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	ATXN2L MAP1A TPRN BCORL1 HELZ DIAPH3 ZCCHC2 CNOT3	1.54e-05	588	66	8	38580884
Pubmed	Crucial roles for interactions between MLL3/4 and INI1 in nuclear receptor transactivation.	KMT2C KMT2D	2.12e-05	4	66	2	19221051
Pubmed	Cancer gene mutation frequencies for the U.S. population.	KMT2C KMT2D	2.12e-05	4	66	2	34645806
Pubmed	Carm1 regulates Pax7 transcriptional activity through MLL1/2 recruitment during asymmetric satellite stem cell divisions.	KMT2D KMT2A	2.12e-05	4	66	2	22863532
Pubmed	MLL2 is required in oocytes for bulk histone 3 lysine 4 trimethylation and transcriptional silencing.	AMHR2 KMT2D	2.12e-05	4	66	2	20808952
Pubmed	MLL3/MLL4 are required for CBP/p300 binding on enhancers and super-enhancer formation in brown adipogenesis.	KMT2C KMT2D	2.12e-05	4	66	2	28398509
Pubmed	KDM5A noncanonically binds antagonists MLL1/2 to mediate gene regulation and promotes epithelial to mesenchymal transition.	KMT2D KMT2A	2.12e-05	4	66	2	37722486
Pubmed	WAVE and Arp2/3 jointly inhibit filopodium formation by entering into a complex with mDia2.	DIAPH3 WASF1	2.12e-05	4	66	2	18516090
Pubmed	Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II.	KMT2C KMT2A	2.12e-05	4	66	2	19703992
Pubmed	Mechanism for DPY30 and ASH2L intrinsically disordered regions to modulate the MLL/SET1 activity on chromatin.	SETD1A KMT2A	2.12e-05	4	66	2	34012049
Pubmed	The super elongation complex (SEC) family in transcriptional control.	POLR2A KMT2A	2.12e-05	4	66	2	22895430
Pubmed	Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.	KMT2D MAP1A RPRD2 DIAPH3 CCDC102A	2.70e-05	184	66	5	32908313
Pubmed	Evolving Catalytic Properties of the MLL Family SET Domain.	KMT2D KMT2A	3.53e-05	5	66	2	26320581
Pubmed	Biochemical reconstitution and phylogenetic comparison of human SET1 family core complexes involved in histone methylation.	SETD1A KMT2A	3.53e-05	5	66	2	25561738
Pubmed	Selective binding of the PHD6 finger of MLL4 to histone H4K16ac links MLL4 and MOF.	KMT2C KMT2D	3.53e-05	5	66	2	31127101
Pubmed	MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia.	KMT2D KMT2A	3.53e-05	5	66	2	28609655
Pubmed	MLL3/MLL4-Associated PAGR1 Regulates Adipogenesis by Controlling Induction of C/EBPβ and C/EBPδ.	KMT2C KMT2D	3.53e-05	5	66	2	32601106
Pubmed	A PTIP-PA1 subcomplex promotes transcription for IgH class switching independently from the associated MLL3/MLL4 methyltransferase complex.	KMT2C KMT2D	3.53e-05	5	66	2	26744420
Pubmed	Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism.	ATXN2L KMT2C AMHR2 DBX1 BICRA WNT10B KMT2A HELZ RERE DIAPH3 USP19	3.74e-05	1327	66	11	32694731
Pubmed	A human MAP kinase interactome.	KMT2C MAP1A BICRA PTPN23 HELZ TNS1 ENKD1	3.81e-05	486	66	7	20936779
Pubmed	A High-Density Map for Navigating the Human Polycomb Complexome.	SETD1A KMT2C KMT2D WIZ BCORL1 KMT2A RERE	4.28e-05	495	66	7	27705803
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	NID2 WIZ MAP1A BICRA TPRN POLR2A HELZ RERE ENKD1 ZNF687	4.59e-05	1116	66	10	31753913
Pubmed	A census of human transcription factors: function, expression and evolution.	SOX10 HNF1A POU6F2 KMT2D DBX1 ZNF335 KMT2A RERE GLIS1	5.29e-05	908	66	9	19274049
Pubmed	Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs.	KMT2D KMT2A	5.29e-05	6	66	2	24176642
Pubmed	BRCT domains of the DNA damage checkpoint proteins TOPBP1/Rad4 display distinct specificities for phosphopeptide ligands.	TICRR RAD9A	5.29e-05	6	66	2	30295604
Pubmed	Coactivator as a target gene specificity determinant for histone H3 lysine 4 methyltransferases.	KMT2C KMT2D	5.29e-05	6	66	2	17021013
Pubmed	SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.	POLR2A HELZ	7.40e-05	7	66	2	15235609
Pubmed	Structural insights into trans-histone regulation of H3K4 methylation by unique histone H4 binding of MLL3/4.	KMT2C KMT2D	7.40e-05	7	66	2	30604749
Pubmed	Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes.	KMT2D KMT2A	7.40e-05	7	66	2	19219072
Pubmed	Unique Role of the WD-40 Repeat Protein 5 (WDR5) Subunit within the Mixed Lineage Leukemia 3 (MLL3) Histone Methyltransferase Complex.	KMT2C KMT2A	7.40e-05	7	66	2	26324722
Pubmed	ASCOM controls farnesoid X receptor transactivation through its associated histone H3 lysine 4 methyltransferase activity.	KMT2C KMT2D	7.40e-05	7	66	2	19556342
Pubmed	Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes.	SETD1A KMT2C KMT2D KMT2A	7.97e-05	119	66	4	23508102
Pubmed	Single-cell profiling of epigenetic modifiers identifies PRDM14 as an inducer of cell fate in the mammalian embryo.	KMT2C KMT2A KDM6B	8.18e-05	44	66	3	24183668
Pubmed	Protein interactome reveals converging molecular pathways among autism disorders.	SPTBN4 ATXN2L IGSF9 RPRD2 ZCCHC2 VWCE SHANK3	9.26e-05	560	66	7	21653829
Pubmed	Four enzymes cooperate to displace histone H1 during the first minute of hormonal gene activation.	KMT2C KMT2D	9.86e-05	8	66	2	21447625
Pubmed	The mutational landscape of lethal castration-resistant prostate cancer.	KMT2D KMT2A	9.86e-05	8	66	2	22722839
Pubmed	H3.3K4M destabilizes enhancer H3K4 methyltransferases MLL3/MLL4 and impairs adipose tissue development.	KMT2C KMT2D	9.86e-05	8	66	2	30335158
Pubmed	BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors.	SETD1A WIZ KMT2A RPRD2	1.26e-04	134	66	4	25452129
Pubmed	Mutation of the Sry-related Sox10 gene in Dominant megacolon, a mouse model for human Hirschsprung disease.	SOX10 CSF2RB	1.27e-04	9	66	2	9560246
Pubmed	The SUMO-specific isopeptidase SENP3 regulates MLL1/MLL2 methyltransferase complexes and controls osteogenic differentiation.	KMT2D KMT2A	1.27e-04	9	66	2	24930734
Pubmed	Transcriptional analyses of two mouse models of spina bifida.	SOX10 DBX1	1.27e-04	9	66	2	23024056
Pubmed	WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development.	KMT2D KMT2A	1.27e-04	9	66	2	15960974
Pubmed	Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression.	KMT2D KMT2A	1.27e-04	9	66	2	16951254
Pubmed	Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells.	SETD1A POLR2A	1.27e-04	9	66	2	22723415
Pubmed	Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.	KMT2D WIZ BCORL1 RERE DIAPH3 ZNF687	1.44e-04	418	66	6	34709266
Pubmed	Wdr82 is a C-terminal domain-binding protein that recruits the Setd1A Histone H3-Lys4 methyltransferase complex to transcription start sites of transcribed human genes.	SETD1A POLR2A	1.58e-04	10	66	2	17998332
Pubmed	Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.	KMT2D WIZ KMT2A RPRD2 RERE	1.59e-04	268	66	5	33640491
Pubmed	Protein phosphatase 1γ isoforms linked interactions in the brain.	TPRN RPRD2 SHANK3	1.77e-04	57	66	3	23080069
Interaction	EGR2 interactions	SOX10 KMT2C KMT2D WIZ BICRA BCORL1 KMT2A RERE	6.74e-08	171	64	8	int:EGR2
Interaction	SETD1B interactions	SETD1A KMT2C KMT2D POLR2A KMT2A RERE	1.37e-07	75	64	6	int:SETD1B
Interaction	HCFC2 interactions	SETD1A KMT2C KMT2D KMT2A HELZ RERE	4.65e-07	92	64	6	int:HCFC2
Interaction	PHF20 interactions	SETD1A KMT2C KMT2A RERE KDM6B	7.03e-07	53	64	5	int:PHF20
Interaction	KDM6A interactions	SOX10 SETD1A KMT2C HNF1A KMT2D KMT2A RERE	8.05e-07	162	64	7	int:KDM6A
Interaction	KMT2D interactions	SOX10 SETD1A KMT2C HNF1A KMT2D POLR2A KMT2A	1.07e-06	169	64	7	int:KMT2D
Interaction	HNF1B interactions	SOX10 KMT2C HNF1A POU6F2 KMT2D WIZ BICRA	2.34e-06	190	64	7	int:HNF1B
Interaction	NFIX interactions	SOX10 SETD1A KMT2C KMT2D WIZ BICRA KMT2A	7.55e-06	227	64	7	int:NFIX
Interaction	ASF1A interactions	KMT2D WIZ BICRA POLR2A BCORL1 KMT2A ZNF687	1.38e-05	249	64	7	int:ASF1A
Interaction	CRX interactions	SOX10 KMT2C KMT2D WIZ BICRA BCORL1 RERE	1.57e-05	254	64	7	int:CRX
Interaction	SETD1A interactions	SETD1A KMT2C KMT2D POLR2A KMT2A RERE	1.65e-05	170	64	6	int:SETD1A
Interaction	ASH2L interactions	SETD1A KMT2C KMT2D ZNF335 KMT2A RERE KDM6B	2.06e-05	265	64	7	int:ASH2L
Interaction	ATN1 interactions	SETD1A KMT2C KMT2A RERE SSPOP SHANK3	2.83e-05	187	64	6	int:ATN1
Interaction	RBBP5 interactions	SETD1A KMT2C KMT2D ZNF335 KMT2A RERE KDM6B	3.43e-05	287	64	7	int:RBBP5
Interaction	FEV interactions	SETD1A KMT2C KMT2D WIZ BICRA KMT2A	4.47e-05	203	64	6	int:FEV
Interaction	DPY30 interactions	SETD1A KMT2C KMT2D KMT2A RERE CNOT3	4.60e-05	204	64	6	int:DPY30
Interaction	ZCCHC2 interactions	HELZ ZCCHC2 SHANK3	5.17e-05	23	64	3	int:ZCCHC2
Interaction	WWTR1 interactions	ATXN2L KMT2D WIZ POLR2A KMT2A PTPN23 RPRD2 DIAPH3	5.49e-05	422	64	8	int:WWTR1
Interaction	KMT2B interactions	SETD1A KMT2C KMT2D KMT2A RERE	5.81e-05	130	64	5	int:KMT2B
Interaction	WDR82 interactions	ATXN2L SETD1A KMT2C KMT2D POLR2A KMT2A	5.84e-05	213	64	6	int:WDR82
Interaction	KMT2A interactions	SETD1A KMT2C KMT2D POLR2A KMT2A RERE KDM6B	6.05e-05	314	64	7	int:KMT2A
Interaction	CXXC1 interactions	SETD1A KMT2C KMT2D KMT2A RERE	6.25e-05	132	64	5	int:CXXC1
Interaction	KMT2C interactions	SETD1A KMT2C HNF1A KMT2D KMT2A	6.71e-05	134	64	5	int:KMT2C
Interaction	ERG interactions	SOX10 KMT2C KMT2D BICRA POLR2A RERE	7.53e-05	223	64	6	int:ERG
Interaction	PHF20L1 interactions	SETD1A KMT2C KMT2A RERE	9.49e-05	75	64	4	int:PHF20L1
Interaction	NCOA6 interactions	SETD1A KMT2C KMT2D ZNF335 KMT2A	9.75e-05	145	64	5	int:NCOA6
Interaction	ELF5 interactions	KMT2C KMT2D WIZ POLR2A ZNF687	1.04e-04	147	64	5	int:ELF5
Interaction	SOX7 interactions	KMT2C KMT2D WIZ BCORL1	1.34e-04	82	64	4	int:SOX7
Interaction	H3C14 interactions	SETD1A KMT2C KMT2D KMT2A RERE	1.38e-04	156	64	5	int:H3C14
Interaction	PAXIP1 interactions	SOX10 SETD1A KMT2C HNF1A KMT2D MAST1 KMT2A	1.39e-04	359	64	7	int:PAXIP1
Interaction	PNMA2 interactions	WIZ MAST1 KDM6B ENKD1 ZNF687 CCDC102A	1.44e-04	251	64	6	int:PNMA2
Interaction	PAX6 interactions	SOX10 KMT2C KMT2D WIZ BICRA SIM2 SHANK3	1.57e-04	366	64	7	int:PAX6
Interaction	KANSL3 interactions	SETD1A KMT2C KMT2A RERE	1.62e-04	86	64	4	int:KANSL3
Interaction	GSC interactions	KMT2C KMT2D BCORL1 RERE	1.69e-04	87	64	4	int:GSC
Interaction	TOP3B interactions	SETD1A KMT2C KMT2D WIZ BCL2L11 ADAMTS7 BICRA ZNF335 POLR2A A4GALT HELZ KDM6B ZNF687 RAD9A	1.71e-04	1470	64	14	int:TOP3B
Interaction	ESRRB interactions	SPTBN4 KMT2C KMT2D WIZ POLR2A ZNF687	1.82e-04	262	64	6	int:ESRRB
Interaction	MDK interactions	RPP25 NID2 SETD1A SHANK3	2.01e-04	91	64	4	int:MDK
Interaction	ZNF608 interactions	SOX10 SETD1A KMT2A RERE	2.18e-04	93	64	4	int:ZNF608
Interaction	HNF4A interactions	SETD1A KMT2C HNF1A KMT2D WIZ BICRA	2.36e-04	275	64	6	int:HNF4A
Interaction	LHX2 interactions	KMT2C KMT2D WIZ BCORL1 ZNF687	2.89e-04	183	64	5	int:LHX2
Interaction	HCFC1 interactions	SETD1A KMT2C KMT2D ZNF335 KMT2A RERE	3.32e-04	293	64	6	int:HCFC1
Interaction	SP7 interactions	KMT2C KMT2D WIZ BICRA RPRD2 RERE	4.03e-04	304	64	6	int:SP7
Interaction	EN1 interactions	KMT2C KMT2D WIZ KMT2A	4.15e-04	110	64	4	int:EN1
Interaction	IGSF9 interactions	IGSF9 SHANK3	4.39e-04	10	64	2	int:IGSF9
Interaction	CBX4 interactions	ATXN2L WIZ KMT2A ARID3C VWCE	4.86e-04	205	64	5	int:CBX4
Interaction	CREBBP interactions	SETD1A HNF1A KMT2D POLR2A KMT2A HELZ KDM6B CNOT3	5.94e-04	599	64	8	int:CREBBP
GeneFamily	Zinc fingers C2H2-type\|Lysine methyltransferases\|PR/SET domain family	SETD1A KMT2C KMT2D KMT2A	2.08e-06	34	49	4	487
GeneFamily	ADAM metallopeptidases with thrombospondin type 1 motif	ADAMTS7 ADAMTS14	1.19e-03	19	49	2	50
GeneFamily	PHD finger proteins	KMT2C KMT2D KMT2A	1.86e-03	90	49	3	88
Coexpression	GSE37532_VISCERAL_ADIPOSE_TISSUE_VS_LN_DERIVED_TREG_CD4_TCELL_DN	SETD1A HNF1A BICRA HELZ RERE KDM6B	2.63e-06	155	66	6	M8944
Coexpression	NRL_DN.V1_UP	KMT2C BCL2L11 POLR2A KMT2A CNOT3	2.51e-05	137	66	5	M2798
Drug	6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	POLR2A BCORL1 PTPN23 RERE KDM6B	1.20e-05	104	65	5	ctd:C000595015
Drug	Flutamide [13311-84-7]; Down 200; 14.4uM; PC3; HT_HG-U133A	RPP25 MAP1A WNT10B KDM6B TNS1 CNOT3	1.76e-05	191	65	6	3803_DN
Drug	Cephalosporanic acid, 7-amino [957-68-6]; Down 200; 14.6uM; PC3; HT_HG-U133A	WIZ MAP1A RERE GMIP KDM6B CNOT3	1.93e-05	194	65	6	4242_DN
Drug	Cefsulodin sodium salt [52152-93-9]; Up 200; 7.2uM; HL60; HT_HG-U133A	ATXN2L WIZ ADAMTS7 DNM3 SIM2 RGS12	2.04e-05	196	65	6	2988_UP
Drug	Piroxicam [36322-90-4]; Down 200; 12uM; PC3; HT_HG-U133A	RPP25 WIZ BICRA WNT10B GMIP CNOT3	2.04e-05	196	65	6	2089_DN
Drug	Nadide [53-84-9]; Up 200; 6uM; MCF7; HT_HG-U133A	SPTBN4 ATXN2L KMT2D DNM3 TNS1 MAP4K2	2.10e-05	197	65	6	6091_UP
Drug	Tetracycline hydrochloride [64-75-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A	WIZ A4GALT DNM3 KMT2A HELZ RGS12	2.22e-05	199	65	6	2243_DN
Drug	Phenylpropanolamine hydrochloride [154-41-6]; Up 200; 21.4uM; PC3; HT_HG-U133A	ATXN2L KMT2D PSKH1 KMT2A KDM6B RGS12	2.22e-05	199	65	6	6699_UP
Drug	sodium 4-phenylbutyrate; Down 200; 1000uM; MCF7; HG-U133A	WIZ BICRA ZNF335 A4GALT RERE KDM6B	2.22e-05	199	65	6	408_DN
Drug	Folinic acid calcium salt [6035-45-6]; Down 200; 7.8uM; MCF7; HT_HG-U133A	WIZ BICRA POLR2A GMIP SIM2 USP19	2.29e-05	200	65	6	3442_DN
Drug	Benzthiazide [91-33-8]; Up 200; 9.2uM; HL60; HT_HG-U133A	ATXN2L POU6F2 KMT2D A4GALT RERE SIM2	2.29e-05	200	65	6	2989_UP
Drug	Dicumarol [66-76-2]; Up 200; 11.8uM; MCF7; HT_HG-U133A	SETD1A WIZ A4GALT KMT2A RGS12	2.11e-04	190	65	5	3848_UP
Drug	Solasodine [126-17-0]; Up 200; 9.6uM; MCF7; HT_HG-U133A	HNF1A HCN4 ADAMTS7 A4GALT KMT2A	2.17e-04	191	65	5	3830_UP
Drug	17-AAG; Down 200; 1uM; HL60; HT_HG-U133A	RPP25 SETD1A BCL2L11 PSKH1 CHST12	2.22e-04	192	65	5	6185_DN
Drug	Gramine [87-52-5]; Up 200; 23uM; MCF7; HT_HG-U133A	SOX10 NID2 CSF2RB MAP1A TNS1	2.27e-04	193	65	5	4118_UP
Drug	indomethacin, USP; Up 200; 20uM; MCF7; HG-U133A	ATXN2L WIZ MAP1A CHST12 RERE	2.27e-04	193	65	5	262_UP
Drug	Mexiletine hydrochloride [5370-01-4]; Down 200; 18.6uM; MCF7; HT_HG-U133A	SETD1A WIZ WNT10B A4GALT RGS12	2.27e-04	193	65	5	3973_DN
Drug	STOCK1N-35215; Down 200; 10uM; PC3; HT_HG-U133A	DNM3 RERE GMIP CNOT3 RGS12	2.33e-04	194	65	5	6380_DN
Drug	Quinethazone [73-49-4]; Down 200; 13.8uM; PC3; HT_HG-U133A	ZNF335 RERE GMIP KDM6B TNS1	2.33e-04	194	65	5	4529_DN
Drug	Ricinine [524-40-3]; Down 200; 24.4uM; MCF7; HT_HG-U133A	ZNF335 WNT10B KMT2A RERE USP19	2.38e-04	195	65	5	6067_DN
Drug	5194442; Up 200; 20uM; MCF7; HT_HG-U133A	ATXN2L SETD1A BCL2L11 RERE RGS12	2.38e-04	195	65	5	6558_UP
Drug	Molindone hydrochloride [15622-65-8]; Down 200; 12.8uM; PC3; HT_HG-U133A	MAP1A RERE KDM6B MAP4K2 CNOT3	2.38e-04	195	65	5	4199_DN
Drug	Melatonin [73-31-4]; Up 200; 17.2uM; PC3; HT_HG-U133A	RPP25 WIZ ZNF335 RGS12 USP19	2.38e-04	195	65	5	6293_UP
Drug	Cyclopenthiazide [742-20-1]; Up 200; 10.6uM; MCF7; HT_HG-U133A	ATXN2L POLR2A RERE SIM2 MAP4K2	2.38e-04	195	65	5	4813_UP
Drug	Sulfachloropyridazine [80-32-0]; Down 200; 14uM; PC3; HT_HG-U133A	NID2 SETD1A WIZ GMIP CNOT3	2.38e-04	195	65	5	4326_DN
Drug	Oxamniquine [21738-42-1]; Up 200; 14.4uM; MCF7; HT_HG-U133A	ATXN2L MAP1A WNT10B A4GALT RERE	2.38e-04	195	65	5	4124_UP
Drug	Bambuterol hydrochloride [81732-46-9]; Up 200; 10uM; MCF7; HT_HG-U133A	ATXN2L SETD1A POU6F2 MAP1A RERE	2.38e-04	195	65	5	3199_UP
Drug	Lobelanidine hydrochloride [6112-86-3]; Down 200; 10.6uM; MCF7; HT_HG-U133A	WIZ RERE SIM2 KDM6B USP19	2.44e-04	196	65	5	2897_DN
Drug	Sulmazole [73384-60-8]; Up 200; 14uM; MCF7; HT_HG-U133A	HNF1A CSF2RB WNT10B RERE RGS12	2.44e-04	196	65	5	4127_UP
Drug	Lisuride (S)(-) [18016-80-3]; Up 200; 11.8uM; HL60; HG-U133A	SLC7A4 WIZ RPRD2 KDM6B CNOT3	2.44e-04	196	65	5	2046_UP
Drug	Zomepirac sodium salt [64092-48-4]; Up 200; 12.8uM; PC3; HT_HG-U133A	SETD1A BCL2L11 HCN4 DIAPH3 TNS1	2.44e-04	196	65	5	4479_UP
Drug	Fluspirilen [1841-19-6]; Down 200; 8.4uM; HL60; HT_HG-U133A	RPP25 SETD1A BCORL1 CHST12 CNOT3	2.44e-04	196	65	5	3086_DN
Drug	Dehydrocholic acid [81-23-2]; Up 200; 9.6uM; PC3; HT_HG-U133A	SETD1A ADAMTS7 KDM6B TNS1 RGS12	2.50e-04	197	65	5	4620_UP
Drug	Methiazole; Down 200; 15uM; PC3; HT_HG-U133A	WIZ BCORL1 RERE TNS1 USP19	2.50e-04	197	65	5	4532_DN
Drug	Indapamide [26807-65-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A	WIZ MAP1A HCN4 KMT2A CNOT3	2.50e-04	197	65	5	3859_UP
Drug	Serotonin hydrochloride [153-98-0]; Down 200; 18.8uM; PC3; HT_HG-U133A	NID2 WNT10B A4GALT DNM3 TNS1	2.50e-04	197	65	5	4673_DN
Drug	2-propylpentanoic acid; Down 200; 50uM; HL60; HT_HG-U133A	RPP25 ATXN2L SETD1A BCL2L11 TNS1	2.50e-04	197	65	5	6181_DN
Drug	Diethylstilbestrol [56-53-1]; Down 200; 15uM; PC3; HT_HG-U133A	DNM3 RPRD2 RERE TNS1 USP19	2.50e-04	197	65	5	4547_DN
Drug	Doxazosin mesylate [77883-43-3]; Up 200; 7.4uM; PC3; HT_HG-U133A	WIZ MAP1A WNT10B A4GALT RERE	2.50e-04	197	65	5	6642_UP
Drug	PHA-00846566E [724718-26-7]; Up 200; 10uM; PC3; HT_HG-U133A	RPP25 MAP1A RERE TNS1 USP19	2.50e-04	197	65	5	7046_UP
Drug	sulindac; Down 200; 100uM; MCF7; HG-U133A	ATXN2L ADAMTS7 KMT2A CHST12 WASF1	2.50e-04	197	65	5	168_DN
Drug	Cefixime [79350-37-1]; Up 200; 8.8uM; MCF7; HT_HG-U133A	SETD1A WNT10B SIM2 KDM6B MAP4K2	2.50e-04	197	65	5	3247_UP
Drug	Lymecycline [992-21-2]; Down 200; 6.6uM; MCF7; HT_HG-U133A	BCL2L11 ZNF335 SIM2 KDM6B RGS12	2.50e-04	197	65	5	3514_DN
Drug	Pronethalol hydrochloride [51-02-5]; Up 200; 15uM; MCF7; HT_HG-U133A	ATXN2L BCL2L11 RERE TNS1 RGS12	2.56e-04	198	65	5	7322_UP
Drug	Tetramisole hydrochloride [16595-80-5]; Down 200; 16.6uM; HL60; HT_HG-U133A	BCL2L11 BICRA DNM3 RERE KDM6B	2.56e-04	198	65	5	2489_DN
Drug	Sulfaguanidine [57-67-0]; Up 200; 18.6uM; MCF7; HT_HG-U133A	SOX10 ATXN2L MAP1A WNT10B RERE	2.56e-04	198	65	5	4839_UP
Drug	Lactobionic acid [96-82-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A	SETD1A WIZ SLC35E1 GMIP RGS12	2.56e-04	198	65	5	3246_DN
Drug	Cefoperazone dihydrate; Up 200; 5.8uM; PC3; HT_HG-U133A	RPP25 HNF1A WNT10B DNM3 TNS1	2.56e-04	198	65	5	6323_UP
Drug	Reserpine [50-55-5]; Down 200; 6.6uM; PC3; HT_HG-U133A	RPP25 WIZ RERE KDM6B TNS1	2.56e-04	198	65	5	4203_DN
Drug	Quinethazone [73-49-4]; Down 200; 13.8uM; PC3; HT_HG-U133A	ATXN2L SETD1A DNM3 KMT2A KDM6B	2.56e-04	198	65	5	3793_DN
Drug	Flumequine [42835-25-6]; Up 200; 15.4uM; PC3; HT_HG-U133A	HCN4 ADAMTS7 A4GALT TNS1 RGS12	2.56e-04	198	65	5	5104_UP
Drug	Monocrotaline [315-22-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A	WIZ POLR2A SLC35E1 DNM3 TNS1	2.62e-04	199	65	5	6771_UP
Drug	clozapine; Up 200; 10uM; HL60; HT_HG-U133A	SOX10 HNF1A ADAMTS7 KMT2A RGS12	2.62e-04	199	65	5	6188_UP
Drug	Coralyne chloride hydrate [38989-38-7]; Up 200; 9.6uM; PC3; HT_HG-U133A	RPP25 ATXN2L BCL2L11 A4GALT RERE	2.62e-04	199	65	5	6317_UP
Drug	Bendroflumethiazide [73-48-3]; Up 200; 9.4uM; HL60; HT_HG-U133A	HCN4 A4GALT RERE SIM2 RGS12	2.62e-04	199	65	5	2555_UP
Drug	Austricine [10180-88-8]; Up 200; 14.2uM; PC3; HT_HG-U133A	ATXN2L HCN4 TNS1 CNOT3 USP19	2.62e-04	199	65	5	4213_UP
Drug	Diazoxide [364-98-7]; Down 200; 17.4uM; MCF7; HT_HG-U133A	SETD1A MAP1A BCL2L11 A4GALT RGS12	2.62e-04	199	65	5	2214_DN
Drug	Lincomycin hydrochloride [859-18-7]; Up 200; 9uM; MCF7; HT_HG-U133A	ATXN2L WIZ HCN4 ADAMTS7 TNS1	2.62e-04	199	65	5	5992_UP
Drug	Nifedipine [21829-25-4]; Up 200; 11.6uM; MCF7; HT_HG-U133A	SETD1A HCN4 WNT10B DNM3 SIM2	2.68e-04	200	65	5	1692_UP
Drug	arachidonic acid sodium salt; Down 200; 10uM; MCF7; HG-U133A	ATXN2L HNF1A WIZ WNT10B ZCCHC2	2.68e-04	200	65	5	604_DN
Drug	Flucytosine [2022-85-7]; Up 200; 31uM; MCF7; HT_HG-U133A	ATXN2L HNF1A WIZ HCN4 ADAMTS7	2.68e-04	200	65	5	6450_UP
Drug	3-Acetylcoumarin [3949-36-8]; Up 200; 21.2uM; HL60; HT_HG-U133A	SOX10 KMT2D ADAMTS7 DNM3 SIM2	2.68e-04	200	65	5	3044_UP
Disease	Kleefstra syndrome 2 (implicated_via_orthology)	KMT2C KMT2D	4.49e-06	2	63	2	DOID:0080598 (implicated_via_orthology)
Disease	Intellectual Disability	SETD1A KMT2C ZNF335 PTPN23 KDM6B WASF1 SHANK3	4.65e-05	447	63	7	C3714756
Disease	neutrophil count	HNF1A BCL2L11 LRP10 RP1L1 BCORL1 DNM3 CHST12 RPRD2 RERE ZCCHC2 KDM6B	1.49e-04	1382	63	11	EFO_0004833
Disease	Ischemic stroke, fibrinogen measurement	ATXN2L HNF1A SHANK3	2.25e-04	55	63	3	EFO_0004623, HP_0002140
Disease	fibrinogen measurement, factor VII measurement	ATXN2L HNF1A SHANK3	2.63e-04	58	63	3	EFO_0004619, EFO_0004623
Disease	fatty acid measurement	HNF1A KMT2A GMIP MAP4K2 RGS12 RAD9A	3.35e-04	436	63	6	EFO_0005110
Disease	testosterone measurement	ATXN2L HNF1A MAP1A BCL2L11 TPRN POLR2A BCORL1 DNM3 ARID3C KDM6B	3.47e-04	1275	63	10	EFO_0004908
Disease	venous thromboembolism, fibrinogen measurement	ATXN2L HNF1A SHANK3	4.03e-04	67	63	3	EFO_0004286, EFO_0004623
Disease	congenital heart disease (implicated_via_orthology)	KMT2C KMT2D KMT2A	4.40e-04	69	63	3	DOID:1682 (implicated_via_orthology)
Disease	teratocarcinoma-derived growth factor 1 measurement	KMT2A TNS1	5.28e-04	16	63	2	EFO_0008297
Disease	open-angle glaucoma	POU6F2 KMT2A RERE GLIS1	7.52e-04	191	63	4	EFO_0004190
Disease	Adenoid Cystic Carcinoma	KMT2C BCORL1 KDM6B	1.29e-03	100	63	3	C0010606
Disease	Sezary Syndrome	KMT2C KMT2D	1.52e-03	27	63	2	C0036920
Disease	Developmental Disabilities	SETD1A SHANK3	1.88e-03	30	63	2	C0008073
Disease	Prostatic Neoplasms	KMT2C KMT2D WNT10B KMT2A RPRD2 CNOT3	2.00e-03	616	63	6	C0033578
Disease	Malignant neoplasm of prostate	KMT2C KMT2D WNT10B KMT2A RPRD2 CNOT3	2.00e-03	616	63	6	C0376358
Disease	cortical surface area measurement	ATXN2L TICRR AMHR2 ADAMTS7 RP1L1 IGSF9 RERE DIAPH3 TNS1	2.13e-03	1345	63	9	EFO_0010736

Protein segments in the cluster

Peptide	Gene	Start	Entry
CGPGLPPPHVSSPQP	ENKD1	171	Q9H0I2
PPTPPSHGPTPGNIF	A4GALT	66	Q9NPC4
QGPSSPSSQPPGLHP	ARID3C	81	A6NKF2
PLLPAPSGSSAPPHP	BCORL1	566	Q5H9F3
PHGSPQGPLAPPASP	BCL2L11	56	O43521
KSSPPSSPGPASPGP	SLC7A4	416	O43246
GHSALPPPPPLPSGG	DIAPH3	571	Q9NSV4
PGPTSLPPFSTPGSP	ADAMTS14	1106	Q8WXS8
PPPHSHPAAPSTGSP	ADAMTS7	1096	Q9UKP4
GTPPSLPPGPSAQSP	ATXN2L	921	Q8WWM7
SHLPPPGSPGTPGSQ	AMHR2	121	Q16671
GPPSGPHNPPPSTSK	CNOT3	456	O75175
SLSPGPQPPKSPGPH	RAD9A	326	Q99638
FPPSPFPSSTGPGPH	PTPN23	771	Q9H3S7
SPHLVPSPAPSPGPG	PTPN23	1081	Q9H3S7
GTLPPPPSGPNSSPL	MAP4K2	426	Q12851
GSPPPPTLPASPSNH	KMT2C	2936	Q8NEZ4
LGPPGPTRSPPGPHT	LRP10	666	Q7Z4F1
SPPPSGPPSATHTPF	MAP1A	996	P78559
APGPLTTSSQPPPPH	GMIP	776	Q9P107
HSSSPAGPVSFPPPP	KDM6B	561	O15054
PCPGPPTAGHTEPPS	PSKH1	61	P11801
APAIPSPGPHSGAPP	DNM3	796	Q9UQ16
PGPLPPSPAHSSSPG	DBX1	306	A6NMT0
PSSTPGSSLPTPPPG	PNPLA1	381	Q8N8W4
PGPGPGPALPAHSSP	HNF1A	291	P20823
GPALPAHSSPGLPPP	HNF1A	296	P20823
PPLGPHPNLGKSPSP	HELZ	1166	P42694
SPPGHSPGPPRTFPS	HCN4	1026	Q9Y3Q4
PSPTQASPPPLPGHT	MAST1	1211	Q9Y2H9
TPPGSTPPHCGPSPE	NID2	996	Q14112
PPSPQPGPPAASHTP	CSF2RB	566	P32927
DSLPPTPPSGTPSPG	CCDC102A	36	Q96A19
GPGEPDSPTPLHPPT	KMT2A	1831	Q03164
PPPLPPSSQSHSPGG	GLIS1	471	Q8NBF1
GPLPPAPHLPPSSTS	BICRA	871	Q9NZM4
PPPPPPGEHSSSGGS	RPRD2	1271	Q5VT52
PHPGPSSPPAAPASK	RPP25	156	Q9BUL9
PGHCPLPSLPTPPAS	SSPOP	1526	A2VEC9
PHAPGPPARASPSGP	TGFBR3L	296	H3BV60
PSQSPGHGLPSPLTP	POU6F2	276	P78424
QPLPPSPCVGSPGPH	PRR23B	231	Q6ZRT6
PSPAATSPPGAPLPH	SIM2	641	Q14190
PPPPGSPLGHSPTAS	WIZ	1141	O95785
PSSAPPGTPQLPTPG	RERE	751	Q9P2R6
PPVSGPGPSPHPSSG	SLC35E1	86	Q96K37
PSGSGHGPCTPPPAP	SETD1A	531	O15047
SRPHTGPPLPTPGPD	CHST12	41	Q9NRB3
VPTHTPGPAPSPSPA	ZCCHC2	961	Q9C0B9
PTPLDSTPPGGAPHP	USP19	401	O94966
LSHPGIPPSPPSCGP	TICRR	1501	Q7Z2Z1
HPTPALPSPGPGPTL	ZP1	191	P60852
PSTSPGSASSPPGPP	RGS12	1271	O14924
RPTPPPSPGGDTPHQ	RP1L1	2276	Q8IWN7
SPSPSPLPSPASGPG	SHANK3	1636	Q9BYB0
SPTPGSPGSPGPSSP	POLR2A	1566	P24928
THSPPGPQQPPASLP	TNS1	826	Q9HBL0
PSGQSHGPPTPPTTP	SOX10	231	P56693
LSPGHSPPSGAPGPP	VWCE	296	Q96DN2
GSAPAPPPPPTHTVQ	SPTBN4	2406	Q9H254
GDPAGTPSPHPDPPS	IGSF9	821	Q9P2J2
SASPPGPAPQHPAAP	UBAP1L	196	F5GYI3
LSPGGSDPPPPPRAH	nan	61	Q6ZR54
DPSLHPPPSPGTPSA	TPRN	256	Q4KMQ1
EPSLPGTPHSPAPPS	ZNF687	131	Q8N1G0
PPSGLHPTPSTAPGP	WASF1	451	Q92558
SLPSPGPGSSPSPGP	WNT10B	176	O00744
HSAAPGPPPSSPGPP	ZNF335	736	Q9H4Z2
LPPTHPGTPKPQGPT	KMT2D	4336	O14686